Nasal Glucagon
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoglycemia
Conditions
Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
Trial Timeline
May 1, 2014 → Aug 1, 2015
NCT ID
NCT02171130About Nasal Glucagon
Nasal Glucagon is a phase 3 stage product being developed by Eli Lilly for Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02171130. Target conditions include Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02402933 | Phase 3 | Completed |
| NCT02806973 | Phase 1 | Completed |
| NCT02806960 | Phase 1 | Terminated |
| NCT02171130 | Phase 3 | Completed |
Competing Products
20 competing products in Hypoglycemia